ACTRIMS 2024 | Guidance for transitioning medications in NMOSD
Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, ON, provides insights into the considerations for transitioning patients with neuromyelitis optica spectrum disorder (NMOSD) from one treatment to another, either due to treatment failure or adverse events (AEs). She emphasizes that factors such as drug efficacy, safety profile, availability, and funding must all be carefully evaluated. In cases where patients are experiencing disease attacks, Dr Rotstein recommends administering prednisone alongside the transitioning medication to manage the attack. Additionally, the time required for the new medication to take effect should also be taken into account. This interview took place during the annual ACTRIMS Forum 2024.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dalia Rotstein reports the following disclosures: I have received research support from MS Canada, the National MS Society, CMSC, University of Toronto Division of Neurology, and Roche Canada. I have received consulting or speaker fees from Alexion, Amgen, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.
